Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Austria: These 4 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Austria: These 4 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can AKEEGA (abiraterone acetate; niraparib tosylate) generic drug versions launch in Austria?

Generic name: abiraterone acetate; niraparib tosylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 10, 2027
Generic Entry Controlled by: Austria Patent E502933

AKEEGA is a drug marketed by Janssen Biotech. There are fourteen patents protecting this drug. There has been litigation on patents covering AKEEGA

See drug price trends for AKEEGA.

The generic ingredient in AKEEGA is abiraterone acetate; niraparib tosylate. Additional details are available on the abiraterone acetate; niraparib tosylate profile page.

When can ZEJULA (niraparib tosylate) generic drug versions launch in Austria?

Generic name: niraparib tosylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: January 10, 2027
Generic Entry Controlled by: Austria Patent E502933

ZEJULA is a drug marketed by Glaxosmithkline. There are eight patents protecting this drug. There has been litigation on patents covering ZEJULA

See drug price trends for ZEJULA.

The generic ingredient in ZEJULA is niraparib tosylate. Additional details are available on the niraparib tosylate profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in Austria?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Austria Patent E488227

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in Austria?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: Austria Patent E480532

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

Last updated: October 16, 2026

Austria is a regulated, reference-priced pharmaceutical market with high public reimbursement, strong generic substitution potential, and growing biosimilar adoption. Market access depends less on national marketing authorization than on inclusion in the Austrian reimbursement system, launch pricing, pharmacy economics, and supply reliability. Originator products retain protection through EU patents, supplementary protection certificates, regulatory exclusivity, data exclusivity, and formulation or method-of-use claims. Generic entry is commercially feasible after core patent expiry, but reimbursement discounts, mandatory price reductions, parallel trade, and procurement pressure limit margins.

Austria Branded and Generic Drug Markets: Patent, Regulatory and Commercial Assessment

How large is the Austrian branded and generic drug market?

Austria has a mixed pharmaceutical market in which patented branded medicines, off-patent originator brands, generics, biosimilars, hospital products, and parallel imports compete under public reimbursement controls.

The outpatient market is dominated by products reimbursed through Austria’s statutory health insurance system. The hospital market has a higher share of tendered and negotiated purchasing, particularly for injectables, anti-infectives, oncology medicines, and biosimilars.

Market characteristic Austria assessment
Population Approximately 9.2 million
Primary regulator Austrian Agency for Health and Food Safety, or BASG
EU marketing authorization European Commission and EMA for centrally authorized products
Reimbursement authority Dachverband der Sozialversicherungsträger and participating social insurance institutions
Key reimbursement tool Erstattungskodex, or EKO
Generic substitution Pharmacist substitution is permitted within Austrian reimbursement rules, but substitution is not equivalent to an automatic substitution mandate in every case
Reference pricing Used through reimbursement and product-group mechanisms
Retail pricing Regulated under Austrian pricing rules
Hospital purchasing Tenders, negotiated contracts, and hospital pharmacy procurement
Patent system Austrian national patents, European patents validated in Austria, and EU supplementary protection certificates
Orange Book No Austrian equivalent to the U.S. FDA Orange Book
Main commercial risks Low reimbursement prices, generic competition, parallel imports, supply obligations, and tender erosion

Austria is generally attractive for companies seeking an EU launch platform, but its standalone revenue opportunity is smaller than Germany, France, Italy, Spain, or the United Kingdom. The commercial value is higher for products with differentiated clinical value, orphan status, hospital demand, or regional supply-chain leverage.

Publicly reported market totals differ depending on whether they include hospital medicines, pharmacy sales, wholesaler turnover, VAT, and reimbursed versus private purchases. Austrian medicines spending is best assessed by product and channel rather than by a single headline market figure.

What is the regulatory pathway for branded and generic medicines in Austria?

Austria uses the EU pharmaceutical framework. A company can obtain marketing authorization through the centralized procedure, decentralized procedure, mutual recognition procedure, or Austrian national procedure, depending on the product.

Branded medicines

Centralized authorization through EMA is mandatory for many biotechnology products, advanced therapies, orphan medicines, and selected innovative products. The European Commission grants a marketing authorization valid across EU member states.

National or decentralized routes remain available for products outside mandatory centralized categories. BASG performs Austrian regulatory functions, including national procedures, pharmacovigilance, inspections, manufacturing oversight, and market surveillance.

After authorization, the company must address:

  1. Austrian product information and packaging.
  2. Pharmacovigilance and risk-management obligations.
  3. Wholesale and distribution compliance.
  4. Pricing and reimbursement.
  5. Inclusion in the EKO where public reimbursement is sought.
  6. National supply and shortage-reporting requirements.

Marketing authorization does not guarantee reimbursement. This separation is commercially important. An originator may legally sell a medicine in Austria but have limited reimbursed access if the product is not listed, is subject to restrictions, or carries a price that payers will not accept.

Generic medicines

Generics rely on the EU abridged application pathway under Article 10 of Directive 2001/83/EC. The applicant generally relies on the reference product’s preclinical and clinical dossier and demonstrates pharmaceutical equivalence and bioequivalence.

Generic applicants must account for:

  • Data and market exclusivity.
  • Patent and SPC status.
  • Pediatric-extension effects.
  • National reimbursement pricing.
  • Bioequivalence requirements for modified-release, inhaled, topical, and complex products.
  • Device and combination-product requirements.
  • Manufacturing-site inspection and Good Manufacturing Practice compliance.

For products authorized through the decentralized or mutual recognition procedure, Austria may act as a concerned member state or reference member state. For centralized products, the generic authorization is EU-wide.

What is the Austrian reimbursement and pricing process?

Austria’s EKO is the central commercial gatekeeper for reimbursed outpatient medicines. Products are grouped into reimbursement categories, with restrictions and price controls that affect prescribing, dispensing, and payer liability.

The EKO uses a traffic-light structure:

EKO category Commercial meaning
Green Box Reimbursement under the ordinary conditions for the listed product
Yellow Box Reimbursement subject to prior approval or defined specialist and clinical restrictions
Red Box Temporary reimbursement pending evaluation, generally subject to approval and review
Non-listed Reimbursement may be unavailable or require exceptional approval

Pricing decisions consider therapeutic value, comparable products, international prices, and budget impact. Generic products commonly enter at a lower price than the originator, and further price reductions can be triggered when competitors enter.

For manufacturers, the principal access question is not whether Austria accepts the EU authorization. It is whether the product can obtain a reimbursed price that supports launch, distribution, and pharmacovigilance costs.

When do branded medicines lose exclusivity in Austria?

There is no single Austrian exclusivity date. Effective loss of protection depends on several rights.

Protection Typical duration or effect
European or Austrian patent Generally 20 years from the effective filing date
Supplementary protection certificate Up to five additional years, subject to EU conditions
Pediatric extension Potential six-month extension to patent or SPC protection
Data exclusivity Generally eight years for the reference product in the EU
Market exclusivity Generally two additional years after data exclusivity
Orphan market exclusivity Generally 10 years, subject to EU exceptions
Orphan extension Potential additional two years for pediatric compliance
Paediatric marketing authorization Product-specific protection linked to the qualifying authorization

EU regulatory exclusivity usually allows a generic applicant to prepare and submit an application during the protected period, while restricting reliance on the reference product’s dossier until the applicable period expires. Patent and SPC rights may still delay commercial launch.

The earliest legally permissible generic launch date must therefore be calculated separately for:

  • Basic patent claims.
  • SPC expiry.
  • Pediatric extension.
  • Formulation patents.
  • Salt, polymorph, crystalline-form, or prodrug patents.
  • Manufacturing-process patents.
  • Method-of-use patents.
  • Device or administration-system rights.
  • Settlement restrictions.

A national Austrian patent can create an Austria-specific barrier, but most important pharmaceutical rights are European patents validated in Austria and litigated under the European patent framework as applied nationally.

What patents protect medicines sold in Austria?

Austrian products can be protected by several patent families:

Composition-of-matter patents

These protect the active pharmaceutical ingredient and usually provide the strongest barrier to generic entry. Their commercial value is highest when the claims cover the marketed molecule broadly and are difficult to invalidate.

Formulation patents

Formulation patents cover controlled release, oral dosage forms, injectable compositions, particle size, excipients, stability, or delivery systems. They can delay substitution even after the basic compound patent expires, although their enforceability depends on claim scope and evidence of infringement.

Method-of-use patents

Method-of-use patents can protect treatment of a defined disease, patient population, dose, biomarker group, or treatment sequence. In Europe, enforcement against a generic can be more difficult where the product has substantial non-infringing uses or where prescribing and dispensing practices do not reliably identify the patented use.

Manufacturing patents

Process claims can protect stereoselective synthesis, purification, crystallization, fermentation, or biologic production. They often create manufacturing barriers rather than direct retail barriers. Enforcement may require access to evidence about the generic manufacturer’s process.

Device and combination patents

Pre-filled syringes, auto-injectors, inhalers, cartridges, pens, and drug-device combinations can carry separate patent rights. These rights are commercially relevant where a generic or biosimilar cannot use the same delivery device without authorization.

How strong is the Austrian patent estate for branded drugs?

Patent strength should be assessed at the European family level, not by counting Austrian validations alone.

Strength factor Strong estate indicator
Core molecule Broad composition claim with substantial remaining term
Validity Survived opposition, nullity, or prior-art challenge
Claim coverage Covers the actual commercial product, not only an unused formulation
SPC Valid SPC with a later expiry date
Enforcement Claim can be enforced against the proposed generic product or process
Commercial relevance Patent blocks reimbursed or clinically standard use
Geographic coverage Valid European patent validated in Austria and key EU markets
Manufacturing control Process rights cover the actual API or finished-dose route
Regulatory protection Patent term aligns with data and market exclusivity

Weak estates commonly depend on narrow formulation claims, method-of-use claims with limited enforceability, patents nearing expiry, or claims that do not cover the generic’s proposed label.

Patent opposition before the European Patent Office can affect Austrian strategy. A successful opposition may remove or narrow a patent across multiple European jurisdictions, while national litigation remains relevant for infringement and validity in Austria.

Which companies are challenging branded products with generics and biosimilars?

Austria’s competitive landscape includes global generic and biosimilar companies, regional manufacturers, and vertically integrated wholesalers. Relevant participants can include Sandoz, Teva, Viatris, STADA, Zentiva, Fresenius Kabi, Accord Healthcare, Krka, Sun Pharma, Hikma, and specialized European biosimilar suppliers. Austrian and German-speaking distribution networks also influence product availability.

The strongest competitive pressure is usually found in:

  • Small-molecule products with multiple suppliers.
  • Chronic therapies with high prescription volume.
  • Hospital injectables.
  • Anti-infectives.
  • Oncology supportive care.
  • Diabetes and cardiovascular medicines.
  • Immunology and oncology biologics after biosimilar entry.

Biosimilar competition is less predictable than ordinary generic competition because substitution, interchangeability, prescriber behavior, tender design, and device differences affect uptake. Austria has supported biosimilar use through reimbursement and prescribing initiatives, but uptake varies by molecule and setting.

What is the biosimilar risk in Austria?

Biosimilar risk is material for high-revenue biologics after loss of European regulatory and patent protection. The commercial impact depends on whether the product is dispensed in retail pharmacies or purchased by hospitals.

Hospital products face rapid price erosion where tenders award contracts to one or a small number of suppliers. Retail biologics may experience slower switching because physicians, patients, and pharmacies remain involved in treatment decisions.

Originators should assess:

  1. Patent and SPC expiry.
  2. Remaining regulatory exclusivity.
  3. Interchangeability and substitution rules.
  4. Hospital tender timing.
  5. Physician prescribing incentives.
  6. Patient support and device continuity.
  7. Number of biosimilar competitors.
  8. Manufacturing capacity and shortage risk.
  9. Litigation or settlement restrictions.
  10. Net price after rebates and mandatory reductions.

A biosimilar launch may be legally possible before all secondary patents expire if the applicant designs around them or prevails in opposition or litigation. A settlement can shift the commercial launch date and may include restrictions on specific formulations, devices, indications, or supply channels.

What is the Orange Book status of medicines in Austria?

Austria has no U.S.-style Orange Book that centrally lists approved products, therapeutic equivalence evaluations, and sponsor-identified patents.

Austria’s equivalent diligence requires reviewing several sources:

  • BASG and EU authorization records.
  • The European Commission’s Union Register.
  • EKO reimbursement listings.
  • European Patent Office records.
  • Austrian Patent Office records.
  • SPC registers.
  • Austrian court and European litigation databases.
  • Product information and national labeling.
  • Public shortage and supply information.

A company conducting an Austria launch or freedom-to-operate review must build its own product-specific patent and regulatory table. U.S. Orange Book listings cannot be assumed to apply in Austria.

How do Paragraph IV challenges work for Austria?

Austria does not use the U.S. Hatch-Waxman Paragraph IV certification system.

Generic applicants instead assess patent risk under European and national law. A company may seek authorization while a patent remains in force, but commercial launch can expose it to infringement proceedings. The legal strategy may involve:

  • Non-infringement arguments.
  • Patent invalidity or revocation.
  • Opposition before the EPO.
  • National nullity proceedings.
  • Declaratory relief.
  • Settlement and license agreements.
  • Launch at risk after internal risk assessment.

Austria therefore has no direct equivalent to a U.S. Paragraph IV notice-letter trigger or automatic 30-month stay. Litigation timing, preliminary injunction risk, patent validity, and launch economics must be analyzed separately.

What patent litigation affects Austrian pharmaceutical launches?

Austrian pharmaceutical disputes can involve infringement, validity, preliminary injunctions, SPC entitlement, employee inventions, unfair competition, and regulatory or reimbursement decisions.

Key litigation considerations include:

  • European patents validated in Austria.
  • National proceedings concerning infringement and validity.
  • EPO opposition outcomes.
  • Preliminary injunction standards and evidence.
  • Parallel litigation in Germany, the Netherlands, France, or the United Kingdom.
  • Cross-border supply and distribution.
  • Generic launch before final judgment.
  • Product liability and shortage exposure.

Patent settlements are possible, but their terms must be reviewed for competition-law risk. A settlement that delays generic entry, allocates markets, restricts supply, or includes value transfers can attract scrutiny under EU competition law. The European Commission’s pharmaceutical-sector enforcement practice remains relevant even when the agreement concerns Austria.

What licensing deals and commercial partnerships are relevant?

Austria is usually covered by broader European or global licensing agreements rather than Austria-only transactions. Common structures include:

  • Territory-specific commercialization licenses.
  • EU rights for generics or biosimilars.
  • Co-promotion arrangements.
  • In-licensing of hospital products.
  • Contract manufacturing and supply agreements.
  • Distribution arrangements with Austrian wholesalers.
  • Device licenses for injectable or inhaled products.
  • Patent licenses tied to settlement agreements.

The most valuable licenses are those that combine regulatory rights, manufacturing capacity, reimbursement support, and freedom to operate. A marketing authorization without supply security or reimbursement access has limited commercial value.

What are the main regulatory opportunities in Austria?

Generic and biosimilar launches

Austria offers a relatively predictable EU regulatory pathway and a public reimbursement system that supports lower-cost alternatives. Companies with efficient manufacturing and reliable supply can compete after core exclusivity expires.

Hospital medicines

Hospital tenders create opportunities for injectable generics, biosimilars, anti-infectives, anesthesia products, and oncology medicines. The risk is rapid price compression and dependence on tender renewal.

Orphan and specialty medicines

Small patient populations can support higher prices where clinical differentiation is strong. The commercial challenge is the evidence and budget-impact scrutiny associated with reimbursement.

Local and regional supply

European manufacturing and reliable inventory can be a competitive advantage during shortages. Austrian buyers may value continuity more highly for critical medicines than for substitutable chronic products.

Digital and decentralized access

Electronic prescribing, pharmacy connectivity, and structured reimbursement data can support targeted launch planning, adherence programs, and demand forecasting, subject to GDPR and Austrian health-data rules.

What are the main regulatory and commercial challenges?

Challenge Effect on manufacturers
Small national market Limits standalone launch economics
Price regulation Reduces gross-to-net realization
Generic price reductions Accelerates erosion after first entry
Parallel imports Complicate price segmentation
Hospital tenders Create volume opportunities but low margins
Supply obligations Increase inventory and compliance costs
Reimbursement restrictions Delay or limit patient access
Patent fragmentation Requires European and Austrian coordination
Biosimilar uncertainty Makes uptake and erosion timing product-specific
Shortage controls Increase reporting, production, and distribution duties

Austrian launch planning should use a net-price model that includes statutory discounts, wholesaler and pharmacy margins, rebates, tender deductions, logistics, pharmacovigilance, and local market-access costs. List price comparisons materially overstate the commercial opportunity.

What generic launch scenarios exist in Austria?

Scenario 1: Clean launch after core patent expiry

The generic enters after patent and SPC expiry with no active secondary rights. Competition is likely to increase quickly, and reimbursement pricing may decline in successive steps.

Scenario 2: Design-around launch

The generic avoids a formulation, device, process, or method-of-use patent. This can support earlier entry but may require a different dosage form, label, manufacturing route, or device.

Scenario 3: Launch after opposition or revocation

The company launches after a favorable EPO or national decision. The main risk is delay caused by appeals or parallel litigation.

Scenario 4: At-risk launch

The company markets before final resolution of a patent dispute. This can capture early volume but exposes the business to injunctions, damages, product withdrawal, and supply disruption.

Scenario 5: Settlement-based entry

The originator and challenger agree on a deferred entry date or licensed launch. The economic value depends on territory, formulation, indication, supply obligations, and competition-law compliance.

How does Austria compare with Germany and other EU markets?

Austria is smaller than Germany but closely connected to German-speaking supply chains and reference-pricing dynamics. Germany generally provides greater volume but has more complex rebate-contract and AMNOG-related commercial considerations. Austria offers a more concentrated access environment, where EKO status, wholesaler reach, and national price negotiations can materially affect uptake.

Compared with France and Italy, Austria has fewer patients but may offer a more manageable regulatory and market-access structure. Compared with smaller Central European markets, it has stronger purchasing power but greater price pressure and higher compliance expectations.

What revenue exposure should originators and generic companies model?

Revenue exposure should be modeled by molecule, channel, and competitor count. The most important variables are:

  • Annual Austrian units.
  • Reimbursed versus private sales.
  • Originator net price.
  • Number and timing of generic entrants.
  • Biosimilar tender awards.
  • Hospital versus retail mix.
  • Patent and SPC expiry.
  • Formulation and device protection.
  • EKO restrictions.
  • Parallel-import share.
  • Supply interruptions.
  • Prescriber switching behavior.

For an originator, Austria is rarely a standalone revenue driver but can contribute to broader European erosion. For a generic company, the market can be attractive when the product has a high-volume indication, limited initial competition, reliable supply, and a reimbursement price that supports multiple suppliers.

Key Takeaways

  • Austria is an EU-regulated pharmaceutical market with strong public reimbursement and significant generic and biosimilar competition.
  • BASG and EMA govern authorization, while EKO listing and Austrian pricing rules determine practical market access.
  • Austria has no FDA Orange Book or Paragraph IV system.
  • Patent analysis must cover European patents validated in Austria, SPCs, formulation claims, method-of-use claims, manufacturing rights, and device patents.
  • Generic and biosimilar entry can occur through design-around, litigation, opposition, licensing, or settlement.
  • Hospital tenders create volume but can produce rapid price erosion.
  • Originator revenue is most exposed after SPC expiry and the arrival of multiple generic or biosimilar suppliers.
  • Supply reliability, reimbursement positioning, and net price are as important as marketing authorization.
  • Austria is commercially strongest as part of a coordinated Central European or EU launch strategy.

FAQs

Does Austria require a separate marketing authorization for a medicine approved by EMA?

No. A centrally authorized product receives an EU-wide authorization. The company still must complete Austrian packaging, pharmacovigilance, distribution, pricing, and reimbursement requirements.

Can a generic launch in Austria before the originator patent expires?

Potentially, but launch before expiry creates infringement risk unless the generic avoids the patent, invalidates it, obtains a license, or relies on another legally available strategy. Regulatory approval alone does not eliminate patent liability.

Are Austrian pharmacies required to substitute generics automatically?

Austria permits generic substitution within its reimbursement framework, but substitution depends on applicable product, prescribing, reimbursement, and dispensing rules. It should not be treated as identical to automatic substitution in every prescription setting.

Are biosimilars interchangeable in Austria?

Interchangeability and substitution depend on the product, regulatory position, clinical setting, payer policy, and professional practice. Hospital procurement can produce faster biosimilar uptake than retail prescribing.

Which Austrian authority controls pharmaceutical reimbursement?

The Dachverband der Sozialversicherungsträger and the Austrian social insurance reimbursement framework control key outpatient reimbursement decisions, including EKO listing and reimbursement categorization.

References

  1. Austrian Agency for Health and Food Safety. (n.d.). Medicinal products and medical devices. BASG.

  2. Austrian Federal Ministry of Social Affairs, Health, Care and Consumer Protection. (n.d.). Erstattungskodex and pharmaceutical reimbursement in Austria.

  3. European Commission. (2001). Directive 2001/83/EC on the Community code relating to medicinal products for human use.

  4. European Commission. (2004). Regulation (EC) No 726/2004 laying down Union procedures for the authorization and supervision of medicinal products and establishing a European Medicines Agency.

  5. European Commission. (2009). Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products.

  6. European Commission. (2019). Regulation (EU) 2019/6 on veterinary medicinal products.

  7. European Medicines Agency. (n.d.). Biosimilar medicines: Overview and regulatory information.

  8. European Patent Office. (n.d.). European patent validation and unitary patent system.

  9. Austrian Patent Office. (n.d.). Patent and supplementary protection certificate information.

  10. European Commission. (2009). Pharmaceutical sector inquiry: Preliminary report and final report materials.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.